Le Lézard
Classified in: Health, Business
Subjects: LAW, SHA

Alta Acts in Response to Stunning Disclosures by Mallinckrodt and Foreshadowing of Bankruptcy Filing


NEW YORK, June 16, 2023 /PRNewswire/ -- Alta Fundamental Advisers LLC ("Alta") filed an SEC Schedule 13D earlier today in connection with investments in the ordinary shares of Mallinckrodt Plc ("Mallinckrodt" or the "Company").  Alta is an institutional investment manager headquartered in New York, NY.   Alta's Schedule 13D disclosed Alta's issuance of a letter earlier today to Mallinckrodt's Board of Directors requisitioning the Board to convene an extraordinary general meeting of Mallinckrodt's shareholders.

Alta Acts in Response to Stunning Disclosures by Mallinckrodt and Foreshadowing of Bankruptcy Filing

Earlier this week, Mallinckrodt issued an SEC Form 8-K filed June 15, 2023 ("8-K") in which it disclosed that it "is actively evaluating the Company's financial situation and considering options" promoted by the Company's debtholders and other "stakeholders." The Company also disclosed its decision to default on credit obligations and that it is considering a "near term" bankruptcy filing.

In response to the 8-K and the troubling disclosures therein, as disclosed in its Schedule 13D, Alta expressed concerns to the Board regarding the Board's ability to manage Mallinckrodt's business affairs and the historical conduct of members of the Board and management.   Alta questioned how the 8-K squares with very recent positive public statements by Mallinckrodt.  It also observed how the purported overnight deterioration in the Company's financial situation eviscerates any lingering confidence in management's candor and compliance with its disclosure obligations, and ability to adapt to and address the circumstances described in the 8-K.

As noted, by its letter, Alta provided the Board with notice of the exercise of Alta's right to compel the Board to call an extraordinary general meeting under the Companies Act 2014.  At this meeting, Alta intends to introduce a resolution to remove and replace some or all of the members of the Board of Directors. Alta believes that it will obtain the support of the majority of the Company's shareholders in connection with this imperative initiative and fully expects to replace some or all of the current Board of Directors at this meeting with individuals who are up to the task.  Alta admonished the current Board of Directors against taking extraordinary action along the lines suggested by the 8-K in the interim.

SOURCE Alta Fundamental Advisers LLC


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: